PathAI’s Year in Review: Delivering on the Promise of AI-Powered Digital Pathology - Part One
Digital pathology and AI are revolutionizing personalized medicine and fueling groundbreaking research with applications in diagnostics, drug development, clinical trials, and beyond. The era of computationally-driven scientific discovery and its clinical applications are redefining healthcare.
This year, PathAI’s leadership reflects on transformative milestones that are redefining the future of pathology. Our impactful partnerships are broadening access to AI-powered solutions across the drug development pipeline and patient care journey. We launched groundbreaking AI products to uncover critical insights in IBD, oncology, and MASH, achieved CE-IVD marked certification for the AISight? platform in Europe, and published cutting-edge research in leading journals. With advancements in foundation models and innovations that integrate histopathology images into real-world data frameworks, PathAI is at the forefront of shaping a new era in precision pathology.
AISight? is for Research Use Only in the US; AISight? Dx is CE-IVD marked in the EEA, UK, and Switzerland. PathExplore?, PathExplore? IOP, IHC Explore?, AIM-MASH, AIM-IHC Breast Panel, MET Predict, IBD Explore? are for Research Use Only. Not for use in diagnostic procedures.?
Letter from Andrew Beck, CEO
From Vision to Reality?
"PathAI was founded in 2016 with a bold mission: to improve patient outcomes through AI-powered pathology. Today, that vision is becoming reality. Digital pathology is no longer a concept of the future—it’s here. We believe that technology’s true potential is realized when it seamlessly integrates into the daily workflows of pathologists. What we’ve built this year are all important pieces of technology, but their impact is only as good as the infrastructure around them. That’s why we focus not just on developing cutting-edge AI tools, but also on creating comprehensive, pathology-centric solutions that truly support pathologists and researchers in their decision-making and reduce their workload. Our strategic partnerships with health-tech industry leaders are essential in making this vision a reality, ensuring our innovations are impactful in real-world settings.?
The global deployment of AISight? Image Management System is a testament to this commitment, and together with our partners, we are creating a future where AI doesn’t just advance pathology—it improves patient outcomes across multiple disease areas worldwide."
PathAI Awards: Deloitte Technology Fast 500?, Boston Globe’s Tech Power Players 50, Largest Healthtech Companies in Massachusetts
Key Strategic Partnerships: Acquisition of PathAI Diagnostics, AI-Enabled Interpretation for Companion Diagnostics
Letter from Eric Walk, Chief Medical Officer
A Vertically Integrated AI Vision Across the Drug Development Lifecycle
"As a pathologist, I’ve witnessed firsthand the challenges and opportunities within our field, and I’m inspired by how PathAI is redefining what’s possible in pathology. We’re advancing AI-powered workflows that promise to drive efficiency across the entire drug development lifecycle, from translational science to diagnostics, addressing critical needs in biomarker discovery, companion diagnostics, and clinical trials. Our Biopharma Lab is aiding numerous clinical trials and our partnerships with biopharma and pathology labs across the globe are accelerating these innovations, delivering real-world impact. The global deployment of our AISight? Image Management System—now supporting over 25 anatomic pathology labs and analyzing more than 20 million slides annually—is a testament to our commitment to transforming pathology and improving patient outcomes. This progress is both exciting and deeply meaningful to me as a pathologist and medical professional.”
Awards: PharmaVoice 100 List
Letter from Ben Glass, Vice President of Product and Translational Research
Building the Next Generation of AI Tools
"PathAI scientists are at the forefront of a transformative shift in healthcare, driving the integration of AI into pathology. Their expertise and dedication power innovations that are shaping the future of clinical practice and drug development. This year, we’ve made significant strides in advancing the tools that will define the future of pathology. Through innovations like PathExplore?, we're pushing the boundaries of what’s possible, from tumor microenvironment (TME) analysis to immuno-oncology profiling (IOP) and fibrosis quantification. IHC Explore? further exemplifies our mission to enhance immunohistochemistry workflows, enabling more precise and scalable biomarker discovery, quantification, and development. These advancements are not merely technical milestones; each day, we’re moving closer to a more efficient, reliable, and personalized approach to drug development, clinical trials, and diagnostics, as demonstrated by our research published in Nature Medicine and Scientific Reports.
While we’ve made great progress, the future is even more exciting. At the core of our next phase is PathAI’s Foundation Model, PLUTO—the PathoLogy Universal TransfOrmer. PLUTO is paving the way for a new era of digital pathology, where AI doesn’t just complement the work of pathologists—it empowers them to deliver more accurate, timely, and actionable insights. As we continue to build AI-driven solutions that address complex clinical challenges, we’re not just redefining the role of pathology; we are helping researchers and pathologists worldwide transform images into quantifiable insights, enabling them to make an even greater impact."
New AI Foundation Model: PLUTO: PathoLogy Universal TransfOrmer
AI Publications: AI powered quantification of nuclear morphology in cancers enables prediction of genome instability and prognosis, Additive MIL: Intrinsically Interpretable Multiple Instance Learning for Pathology, Interpretability analysis on a pathology foundation model reveals biologically relevant embeddings across modalities, Spatial mapping of immunosuppressive CAF gene signatures in H&E-stained images using additive multiple instance learning
Letter from Elizabeth Storti, Chief People Officer
Our Organization, Our Mission, and Beyond: Embracing Diversity, Empowering Innovation: Celebrating Our Team's Impact and Values
"Our values are at the heart of everything we do, and this year, they have guided us in achieving remarkable milestones. Being named one of Boston Business Journal's Best Places to Work for 2024 reflects our commitment to fostering a culture that is truly “One PathAI”—a team united in our shared mission to improve patient outcomes. We embody a “Patients First” mindset, always putting the needs of those we serve at the forefront of our efforts. This year, we also embraced our “All In” spirit as we gathered our global team during Boston Week 2024 to contribute to our local community, demonstrating our collective dedication to making a positive impact beyond the office. Additionally, in honor of Womxn's Day 2024, we celebrated the invaluable contributions of women in STEM at PathAI, recognizing their role in shaping our innovative culture and driving forward our mission. Through our values of accountability, humility, and being “All In,” we continue to empower our team to push boundaries and work together towards a better, more equitable future in healthcare."
Team Highlights: Boston Business Journal - Best Places to Work 2024,? Boston Week 2024 - Gathering our global team to aid our local community, Womxn’s Day 2024 - Celebrating the contributions of Women in STEM at PathAI
As we look ahead to 2025, PathAI is poised for a groundbreaking year in AI-powered digital pathology. Building on this year’s achievements—including advancements in diagnostics, oncology, MASH, and IBD—we are prepared to make an even greater impact. From optimizing pathologist workflows with AISight? to advancing clinical trials and drug development through our Biopharma Lab, we remain at the forefront of innovation. By strengthening key partnerships and advancing AI-driven solutions like PathExplore? and IHC Explore?, we are accelerating progress in precision medicine. In 2025, we aim to empower clinicians, drive transformative research, and elevate patient outcomes, unlocking the full potential of AI in pathology. Happy New Year, indeed!
CEO at FlexMade, Software Outsourcing and Outstaffing Services | Empowering businesses through custom software development
1 个月??
Sócio - Diretor Comercial da Touch Health
2 个月Que ótimo